DURECT CORP. overview

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., May 13, 2025 Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif. , May 13, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial...

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., March 26, 2025 Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif. , March 26, 2025...

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., March 19, 2025 CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that...

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif., Feb. 4, 2025 CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. Presentation details are as follows: Date and time: Tue, Feb 11 at 2:00-2:30 PM...

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence PR Newswire CUPERTINO, Calif., Jan. 28, 2025 The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence . The full article,...

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million PR Newswire CUPERTINO, Calif., Nov. 25, 2024 CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET ® line of osmotic pumps to Lafayette...

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., Nov. 13, 2024 - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif. , Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and...

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., Nov. 6, 2024 CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on...